MTOR and small cell lung carcinoma: Many of the drugs targeting the PI3K pathway are currently under clinical evaluation; however, only one phase I clinical trial (NCT02069158) is currently investigating the potential use of the dual PI3K/mTOR inhibitor PF-05212384 in combination with paclitaxel and carboplatin for the treatment of SCLC [50].